Mankind Pharma Ltd.

₹2,394

14 (0.6%)

MANKIND Share Price

Pharmaceuticals & Biotechnology

As on August 19, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 98,520 Cr

P/E Ratio51.66

Dividend Yield0.04 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	2,396.9	Bearish
10-DMA	2,415.69	Bearish
20-DMA	2,469.29	Bearish
50-DMA	2,478.11	Bearish
100-DMA	2,374.33	Bullish
200-DMA	2,275.75	Bullish

Historical Performance

1 Year

-3.9%

3 Years

29.5%

5 Years

N/A

10 Years

N/A

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Net Sales	1,42,776	1,22,074	1,02,604	87,494	77,816
Total Expenditure	1,06,553	91,870	77,453	68,475	57,910
Other Income	3,588	5,368	2,802	1,286	1,960
Operating Profit	39,812	35,573	27,954	20,305	21,866
Interest	6,442	4,320	342	458	598
Depreciation	8,862	6,212	3,784	3,259	1,666
Profit Before Tax	23,327	25,163	23,979	16,712	19,746
Consolidated Net Profit	19,129	19,910	19,129	12,819	14,335
Adjusted EPS	46	48	48	32	36

Compounded Sales Growth

10 Years:29.3

5 Years:18.1

3 Years:10.3

TTM:3.2

Compounded Profit Growth

10 Years:28.7

5 Years:8.6

3 Years:8.3

TTM:-0.8

Stock Price CAGR

10 Years:N/A

5 Years:N/A

3 Years:9

TTM:-4.5

Return on Equity

10 Years:15.7

5 Years:35.8

3 Years:47.8

last year:46.3

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Share Capital	413	413	401	401	401
Total Reserves	1,62,113	1,42,475	92,998	73,951	61,152
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	46,865	74,199	1,873	1,992	1,687
Other Current Liabilities	37,024	13,351	7,555	3,861	4,729
Short Term Borrowings	6,389	25,131	1,515	1,150	7,946
Total Liabilities	2,77,548	2,76,516	1,18,829	96,857	91,084
Capital Work in Progress	6,548	3,061	2,071	4,932	6,699
Long Term Loans & Advances	5,547	2,931	1,640	1,875	1,639
Currents Investments	15,373	16,908	22,581	10,755	8,745
Short Term Loans and Advances	9,567	10,108	10,935	6,567	8,043
Total Current Assets	69,515	69,856	65,655	43,246	44,038
Total Assets	2,77,548	2,76,516	1,18,829	96,857	91,084
Adjusted Book Value	394	346	233	186	154

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 51.66, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered a moderate 3-year price CAGR of 9.2%, reflecting average market performance.
The stock carries a low beta of 0.7, suggesting lower volatility than the broader market.
In the last financial year, the company reported an EBITDA of ₹39812 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹142776 million, indicating a large and established business.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 955078.6

No. of Shares: 399 (Approx)

Performance:-4.5%

-44921.4

NIFTY Performance: -3.9%

1 day Top Gainers